Search

Displaying results 2911 - 2920 of 10000 in total

Target
Antigen peptide transporter 1
go.drugbank.com/bio_entities/BE0003109
TransporterHumans
In complex with TAP2 mediates unidirectional translocation of peptide antigens from cytosol to endoplasmic reticulum (ER) for loading onto MHC class I (MHCI) molecules (PubMed:25377891, PubMed:25656091 … Subsequently ATP hydrolysis resets the transporter to the 'inward facing' state for a new cycle (PubMed:11274390, PubMed:25377891, PubMed:25656091).
Synonyms: Peptide transporter involved in antigen processing 1
Drug
L-tartaric acid
go.drugbank.com/drugs/DB09459
Approved
Tartaric acid is a white crystalline organic acid that occurs naturally in many plants, most notably in grapes.Tartaric is an alpha-hydroxy-carboxylic acid, is diprotic and aldaric in acid characteristics … , and is a dihydroxyl derivative of succinic acid.
Mixtures: SAL G., ENHOŞ MEYVE TUZU , 20 (SADE) ADETSynonyms: (+)-(R,R)-tartaric acid, (R,R)-Tartaric acid
Drug
Trovafloxacin
go.drugbank.com/drugs/DB00685
ApprovedWithdrawn
It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. … It was shown to be more effective against Gram-positive bacteria than Gram-negative bacteria when compared to previous fluoroquinolones.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
Drug
Acenocoumarol
go.drugbank.com/drugs/DB01418
ApprovedInvestigational
This prevents carboxylation of vitamin K-dependent clotting factors, II, VII, IX and X, and interferes with coagulation. … Patients on acenocoumarol are prohibited from giving blood.
Categories: Vitamin K Antagonists
Drug
Pegaptanib
go.drugbank.com/drugs/DB04895
ApprovedWithdrawn
Pegaptanib is a polynucleotide aptamer. Pegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability. … Pegaptanib was granted FDA approval on 17 September 2004.[L17903]
Drug
Givinostat
go.drugbank.com/drugs/DB12645
ApprovedInvestigational
[L50316,A263446] Givinostat was granted FDA approval in March 2024 for the treatment of patients ≥6 years of age with Duchenne muscular dystrophy (DMD). … [L50311,L50316] It is the first non-steroidal drug approved to treat patients with all genetic variants of DMD.[L50316]
Drug
Sipavibart
go.drugbank.com/drugs/DB21908
ApprovedInvestigational
[A274088] Sipavibart is approved for the pre-exposure prophylaxis treatment of COVID-19 in immunocompromised patients.[L53418] … [L53418] Sipavibart gained its first global approval in Japan in December 2024.[A274088] It was later approved in Europe in January 2025 and in Canada in March 2025.
Categories: Antiinfectives for Systemic Use
Drug
Cladribine
go.drugbank.com/drugs/DB00242
ApprovedInvestigational
[A350] Cladribine was first approved in the United States in 1993 [A263713] initially as a treatment for a number of hematological malignancies; currently, it is approved for the treatment of hairy cell … [A263733] In 2017 in Europe and in 2019 in the United States, cladribine was also approved for the treatment multiple sclerosis.[A263718]
Drug
Ceruletide
go.drugbank.com/drugs/DB00403
Approved
Caerulein is a specific decapeptide similar in action and composition to the natural gastrointestinal peptide hormone cholecystokinin. … It exerts stimulatory effects on the gastric, biliary, and pancreatic secretion, as well as on certain smooth muscles.
Categories: Tests for Bile Duct Patency
Drug
Ethionamide
go.drugbank.com/drugs/DB00609
ApprovedInvestigationalWithdrawn
It also may be used for treatment of leprosy. (From Smith and Reynard, Textbook of Pharmacology, 1992, p868)
Categories: Antiinfectives for Systemic Use, Drugs for Treatment of Tuberculosis